Skin-improving cosmetic composition

Abstract

The present disclosure relates to a cosmetic composition for improving skin conditions, which contains a peptide for improving skin conditions. The peptide for improving skin conditions of the present disclosure or a derivative thereof exhibits a significantly excellent effect of improving skin conditions. The peptide or a derivative thereof can be used as an active ingredient in a functional cosmetic composition or a topical skin preparation composition that can be used on the skin.

Description

Technical Field

[0001] This application claims priority based on Korean Patent Application No. 10-2022-0172978 filed on December 12, 2022 and Korean Patent Application No. 10-2023-0100598 filed on August 1, 2023, and all contents disclosed in the specification and drawings of the said applications are incorporated into this application.

[0002] The present disclosure relates to a cosmetic composition for improving skin condition comprising a peptide for improving skin condition. Background Art

[0003] Skin wrinkles generally occur due to strong muscle contraction, or result from maintaining a posture that causes strong muscle contraction for a long time. Nowadays, wrinkles that appear when making facial expressions (expression wrinkles) and wrinkles associated with aging are often treated with Botox (botulinum toxin type A). Botox improves skin wrinkles by paralyzing the muscles around the eyes and the muscles on the forehead. However, since Botox must be administered by a doctor via subcutaneous injection, it has the disadvantages of restricted use, high cost, and strong toxicity. In addition, the effect of Botox only lasts for about 3 to 6 months, so repeated treatments are required.

[0004] The mechanism of action of Botox is to paralyze muscles by selectively blocking the secretion of acetylcholine at the neuromuscular synapse. This occurs through cleavage of a protein called SNAP-25. In addition, the N-terminal amino acid sequence of SNAP-25 (H-Glu-Glu-Met-Gln-Arg-Arg-NH2) also functions at the synapse in Ca ++- It induces muscle relaxation by inhibiting the secretion of addictive neurotransmitters. The locally applicable compound developed from this, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, marketed under the trademark name Argirelline(trademark), is 5000 times weaker than Botox, making it easy to administer and virtually non-toxic. However, its muscle relaxation effect is very weak and uneven, its wrinkle-improving effect is unsatisfactory, and its protein degradation stability is insufficient.

[0005] Small peptides or peptide compounds are formed by enzymatic degradation within the extracellular matrix of skin cells. These peptides or peptide compounds, called "matrikines," possess important signaling functions and can therefore regulate cell activity. Consequently, various peptides or peptide compounds obtained by extraction or synthesis have been proposed as active ingredients in cosmetics. For example, the lipid peptides Pal-KTTKS and Pal-GHK / Pal-GQPR mixture, marketed under the trademark MATRIXYL™, are considered to be collagen fragments. In vitro experiments have measured their collagen synthesis-stimulating effects, and in vivo experiments have shown improvements in skin hardness, elasticity, density, thickness, and microrelief (wrinkles and fine lines). Thus, novel peptide compounds that can correct skin defects and improve skin condition are promising active ingredients in the cosmetics industry.

[0006] Drugs delivered through the skin are convenient to use and are employed in a variety of fields and forms. While these drugs that penetrate the skin are primarily intended to be delivered to the systemic circulatory system via the skin, they are also used to directly deliver active ingredients to the skin itself, such as in atopic dermatitis treatments and cosmetics for skin whitening or wrinkle reduction.

[0007] Recently, peptides have been developed that exhibit effects similar to Botox in the skin, but reduce muscle contraction in a non-paralytic manner without the side effects of toxins. Such peptides temporarily block the secretion of neurotransmitters such as acetylcholine, which are responsible for muscle cell contraction, thereby alleviating wrinkle formation. However, excessive use of such peptides carries the risk of side effects, and there are limitations to their use, such as their ability to act only in areas with a high density of nerves. [Overview of the Initiative] [Problems that the invention aims to solve]

[0008] The problem that this disclosure aims to solve is to improve the shortcomings of conventional skin-improving peptides and provide a composition that has excellent skin-improving effects and is safe for the human body. [Means for solving the problem]

[0009] The inventors of this invention have been working to develop a composition that improves upon the problems of conventionally used peptides for improving skin condition, such as side effects and precautions for use, and that is safe for use on the human body while exhibiting excellent skin condition improving effects, without the drawbacks of having weak effects. As a result, the inventors discovered a specific peptide sequence that exhibits skin condition improving effects. The inventors found that when a peptide consisting of a specific amino acid sequence whose effectiveness has been stabilized through mutation and sequence optimization is applied to the skin, the skin condition is remarkably improved, and thus the present invention was completed.

[0010] This disclosure provides a peptide or derivative thereof comprising the amino acid sequence of the following chemical formula I. The peptide or derivative thereof of this disclosure may be used to improve the condition of the skin, preferably the appearance of the skin. <Chemical formula I> X1-X2-X3-(SSCF)-Y1-Y2-Y3

[0011] In the amino acid sequence of the aforementioned chemical formula I, X1 may be K or not present, X2 may be G or not present, X3 may be R or not present, Y1 may be V or not present, Y2 may be D or not present, and Y3 may be C or not present.

[0012] In one aspect of this disclosure, preferably, the amino acid sequence of chemical formula I may include at least one amino acid sequence from among X1-X3 and Y1-Y3.

[0013] In one aspect of this disclosure, the amino acid sequence of chemical formula I may be any one of the following sequence numbers. -Sequence ID 1:KGRSSCFVDC -Sequence code 2:KGRSSCFVD -Sequence code 3:KGRSSCF -Sequence code 4:KGRSSCFV -Sequence ID 5: RSSCFVDC -Sequence ID 6:SSCFVDC -Sequence code 7:GRSSCFVD - Sequence ID 8: RSSCFVD -Sequence ID 9:SSCFVD -Sequence ID 10:KGSSCFVDC -Sequence ID 11:KGRSSCFDC -Sequence code 12:KGRSSCFVC - Sequence ID 13: RSSCF

[0014] This disclosure provides a cosmetic, topical skin preparation, or pharmaceutical composition for improving skin condition, comprising a peptide or derivative thereof, comprising an amino acid sequence of chemical formula I selected from any one of the amino acid sequences of sequence numbers 1 to 13. Preferably, the skin condition improving composition may be a cosmetic composition.

[0015] In one aspect of this disclosure, the peptide or its derivative may contain an amino acid sequence having at least 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of chemical formula I. Preferably, the peptide or its derivative may contain an amino acid sequence having 80% or more sequence identity with the amino acid sequence of chemical formula I.

[0016] In one aspect of this disclosure, the peptide or its derivative may contain an amino acid sequence having at least 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of the amino acid sequences of Sequence IDs 1 to 13. Preferably, the peptide or its derivative may contain an amino acid sequence having 80% or more sequence identity with any one of the amino acid sequences of Sequence IDs 1 to 13.

[0017] In one aspect of this disclosure, a peptide or derivative thereof containing the amino acid sequence of chemical formula I may be included in the composition in an amount of 0.0001 to 50% by weight, preferably 0.001 to 30% by weight, and more preferably 0.001 to 1% by weight, based on the total weight of the composition. When the content of the peptide or derivative thereof is within the above range, the skin condition improving effect may be superior.

[0018] In one aspect of this disclosure, a peptide or derivative thereof comprising the amino acid sequence of chemical formula I may be used for improving skin condition, preferably for wrinkles, skin elasticity, or skin sebum care.

[0019] In one aspect of this disclosure, the term “peptide” means both natural and synthetic peptides containing 15 or fewer amino acids, and may include naturally occurring or commercially available peptides. Such peptides include derivatives, isomers, or complexes with metal ions.

[0020] In one aspect of the present disclosure, the peptide comprising the amino acid sequence of Chemical Formula I may be a pure peptide, an L-isomer, a D-isomer, or a mixture thereof, and is preferably a naturally occurring L-isomer.

[0021] In one aspect of the present disclosure, the peptide comprising the amino acid sequence of Chemical Formula I may be in the form of a salt, preferably any salt form commonly used in cosmetic compositions or pharmaceutical compositions, for example, it may be a hydrochloride or acetate.

[0022] In one aspect of the present disclosure, a derivative of a peptide comprising the amino acid sequence of Chemical Formula I refers to a derivative that has modification or addition of a chemical functional group but no change in the carbon backbone. The derivatives include peptides whose N-terminus, C-terminus, etc. are chemically modified, or peptides whose amino acids are modified by addition, substitution, or deletion. The peptide derivative may be a lipophilic derivative, for example, may be a palmitoyl derivative. Further, the peptide derivative may be a derivative bound with a dansyl group. Further, the peptide derivative may be a derivative bound with an acetyl group.

[0023] In one aspect of the present disclosure, even if the peptide comprises an amino acid having a reverse sequence structure of the amino acid of Chemical Formula I, it can still exhibit a skin condition improving effect. Preferably, the amino acid sequence having the reverse sequence structure may be any one of the amino acid sequences of SEQ ID NOs: 14 to 16 below. - SEQ ID NO: 14: CDVFCSSRGK - SEQ ID NO: 15: DVFCSSRGK - SEQ ID NO: 16: FCSSRGK

[0024] In one aspect of this disclosure, the peptide comprising the amino acid sequence of chemical formula I includes analogues having modifications and / or additions of chemical functional groups, resulting in additional changes to the carbon skeleton. Furthermore, the peptide may include peptides having sequences that differ from the wild-type amino acid sequence it contains by one or more amino acid groups. Amino acid exchanges in proteins and polypeptides that do not alter the overall activity of the molecule are known in the art to which this invention belongs. Common exchanges may be between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, or Asp / Gly. Also, peptides may include those in which mutations or modifications of the amino acid sequence increase structural stability or activity to heat, pH, etc.

[0025] The peptide may be produced by conventional chemical peptide synthesis methods, or by amplifying the gene encoding the peptide by PCR, or by synthesizing it by a known method, and then cloning it into an expression vector for expression. The peptide also contains a complex with a metal ion, such as copper, zinc, manganese, and magnesium. When chemically synthesizing the peptide using instruments, it can be synthesized using an automated peptide synthesizer with liquid-phase (Convergent Solution Phase Synthesis) and solid-phase (Solid Phase Peptide Synthesis) methods.

[0026] Furthermore, this disclosure provides polynucleotides encoding peptides or derivatives thereof comprising the amino acid sequence of chemical formula I. The polynucleotides may be mutated by substitution, deletion, insertion, or combination thereof of one or more bases. When the nucleotide sequence is prepared by chemical synthesis, synthetic methods well known in the art, such as those described in the literature (Engels and Uhlmann, Angew., Chem Int Ed Engl., 37:73-127, 1988), may be used, and synthesis may also be carried out by triester, phosphite, phosphoramidite and H-phosphate methods, PCR and other autoprimer methods, oligonucleotide synthesis methods on solid supports, etc.

[0027] This disclosure provides polynucleotides of sequence numbers 17 to 19 that encode any one of the amino acid sequences of sequence numbers 1 to 3. The polynucleotide of sequence number 17 encodes the amino acid sequence of sequence number 1, the polynucleotide of sequence number 18 encodes the amino acid sequence of sequence number 2, and the polynucleotide of sequence number 19 encodes the amino acid sequence of sequence number 3. -SEQ ID NO:17:AAA GGC CGC AGC AGC TGC TTT GTG GAT TGC -SEQ ID NO:18:AAA GGC CGC AGC AGC TGC TTT GTG GAT -SEQ ID NO:19:AAA GGC CGC AGC AGC TGC TTT

[0028] Furthermore, this disclosure provides an expression vector comprising the polynucleotide and a transformant comprising the expression vector. This disclosure also provides a method for producing the skin condition improving peptide or a derivative thereof using the transformant.

[0029] In this disclosure, “expression vector” means a gene construct that is a recombinant vector capable of expressing a target peptide in a host cell and comprises essential regulatory elements operably linked to the expression of a gene insert. The expression vector comprises expression regulatory elements such as a start codon, a termination codon, a promoter, and an operator, wherein the start codon and termination codon are generally considered to be part of the nucleotide sequence that codes the polypeptide, must act in the organism when the gene construct is administered, and must be in frame with the coding sequence. The promoter may be constitutive or inductive.

[0030] The expression vector may include a signal sequence for polypeptide efflux to facilitate the separation of the protein from the cell culture medium. A specific start signal may be required for efficient translation of the inserted nucleic acid sequence. The signal may include an ATG start codon and adjacent sequences. In some cases, it may be necessary to provide an exogenous translational regulatory signal, which may include an ATG start codon. These exogenous translational regulatory signals and start codons can be from a variety of natural and synthetic sources. Expression efficiency may be improved by introducing appropriate transcription or translation enhancers.

[0031] Furthermore, the expression vector may optionally further include a protein tag that can be removed using an endopeptidase to facilitate detection of the peptide or its derivatives. The “tag” means a molecule exhibiting quantifiable activity or properties, and may be a fluorescent molecule containing a polypeptide fluorescent substance such as a chemifluorescent substance like fluorescein, a fluorescent protein (GFP), or an associated protein, or an epitope tag such as a Myc tag, Flag tag, histidine tag (His tag), leucine tag, IgG tag, or streptavidin tag. When an epitope tag is used, the epitope tag may preferably consist of 6 or more amino acid residues, more preferably a peptide tag consisting of 8 to 50 amino acid residues.

[0032] In this disclosure, the expression vector may include a nucleotide sequence encoding the peptide or a derivative thereof. The expression vector is not particularly limited as long as it can produce the peptide or its derivatives, but preferably plasmid DNA or phage DNA can be used, and more preferably, commercially developed plasmids (pUC18, pBAD, pIDTSAMRT-AMP, etc.), plasmids derived from Escherichia coli (pYG601BR322, pBR325, pUC118, pUC119, etc.), plasmids derived from Bacillus subtilis (pUB110, pTP5, etc.), plasmids derived from yeast (YEp13, YEp24, YCp50, etc.), phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11, λZAP, etc.), animal virus vectors (retrovirus, adenovirus, vaccinia virus, etc.), insect virus vectors (baculovirus, etc.) can be used. Since the expression levels of the aforementioned expression vectors differ depending on the host cell, it is preferable to select and use the host cell that is most suitable for the purpose.

[0033] In this disclosure, the transformant can be produced by introducing the expression vector into a host and performing transformation. The transformant can be used to express the polynucleotide contained in the expression vector to produce the skin condition improving peptide or its derivatives. The transformation can be carried out by various methods, including, but is not limited to, the CaCl2 precipitation method, the Hanahan method which is an improved version of the CaCl2 precipitation method using a reducing agent called dimethyl sulfoxide (DMSO), electroporation, calcium phosphate precipitation, plasmofusion, stirring method using silicon carbide fibers, transformation mediated by agrobacteria, transformation using polyethylene glycol (PEG), transformation mediated by dextran sulfate, lipofectamine, and drying / inhibition. Furthermore, the host used to produce the transformants may include, but is not limited to, bacterial cells such as Escherichia coli, Streptomyces, and Salmonella tiphimuria; yeast cells such as Saccharomyces cerevisiae and Schizosaccharomyces pombe; fungal cells such as Pichia pastris; insect cells such as Drosophila melanogaster and Sf9 moth cells; animal cells such as CHO, COS, NSO, 293, and Bowes melanoma cells; or plant cells.

[0034] The transformant can also be used in a method for producing the peptide or a derivative thereof. Specifically, a method for producing the peptide or a derivative thereof of the present disclosure may include: (a) culturing the transformant to obtain a culture; and (b) recovering the peptide or a derivative thereof of the present disclosure from the culture.

[0035] In this disclosure, “cultivation” refers to a method of growing microorganisms under appropriately artificially controlled environmental conditions. The method for culturing the transformants can be carried out using methods well known in the art. Specifically, the culturing can be carried out by continuous cultivation in a batch process, or in an injection batch or repeated injection batch process.

[0036] The culture medium used for the aforementioned cultivation must meet the requirements of the specific strain in an appropriate manner, while adjusting the temperature, pH, etc., under aerobic conditions, within a standard culture medium containing a suitable carbon source, nitrogen source, amino acids, and vitamins. Suitable carbon sources include glucose and xylose mixed sugars as the main carbon source, as well as sugars and carbohydrates such as sucrose, lactose, fructose, maltose, starch, or cellulose; oils and fats such as soybean oil, sunflower oil, castor oil, or coconut oil; fatty acids such as palmitic acid, stearic acid, and linoleic acid; glycerol; alcohols such as ethanol; and organic acids such as acetic acid. These substances can be used individually or in mixtures. Suitable nitrogen sources include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, and ammonium nitrate; and organic nitrogen sources such as amino acids (glutamic acid, methionine, glutamine, etc.), peptone, NZ-amine, meat extracts, yeast extracts, malt extracts, corn maceration, casein hydrolysates, fish or their decomposition products, defatted soy cake or its decomposition products. These nitrogen sources can be used individually or in combination. The culture medium may contain monopotassium phosphate, dispotassium phosphate, and their corresponding sodium salts as phosphorus sources. Inorganic compounds such as sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, and calcium carbonate may be used. Other essential growth substances such as amino acids and vitamins may also be used.

[0037] Furthermore, a precursor suitable for the culture medium may be used in the culture medium. The raw materials may be added to the culture in a batch, fed-batch, or continuous manner during the culture process by a method suitable for the culture, but are not limited to these. The pH of the culture may be adjusted by using basic compounds such as sodium hydroxide, potassium hydroxide, and ammonia, or acidic compounds such as phosphoric acid or sulfuric acid in a suitable manner. In addition, antifoaming agents such as fatty acid polyglycol esters may be used to suppress bubble formation. To maintain an aerobic state, oxygen or oxygen-containing gas (e.g., air) is injected into the culture medium. The temperature of the culture is usually 27°C to 37°C, preferably 30°C to 35°C. The culture can be continued until the maximum amount of the peptide or its derivative is obtained, and for this purpose, it can usually be cultured for 10 to 100 hours.

[0038] Furthermore, the step of recovering the peptide or its derivatives from the culture can be carried out by methods known in the art. Specifically, the recovery method can be, but is not limited to, centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, fractional dissolution (e.g., ammonium sulfate precipitation), or chromatography (e.g., ion exchange, affinity, hydrophobicity, and size exclusion).

[0039] In one aspect of this disclosure, the term "topical skin preparation" means a solid, semi-solid, or liquid topical preparation that can be easily applied to the skin by mixing an active ingredient with various bases such as oils and fats, petrolatum, lanolin, or glycerol. Such topical dosage forms are not particularly limited, but powder, gel, ointment, cream, liquid, or aerosol dosage forms are preferred.

[0040] In one aspect of the present disclosure, the pharmaceutical composition may further comprise a peptide or derivative thereof comprising the amino acid sequence of chemical formula I, as well as a drug that is introduced into the body through the skin or delivered to the organs of the skin itself. The pharmaceutical composition may further comprise suitable carriers, excipients, or diluents commonly used in the industry.

[0041] The pharmaceutical composition may have one dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterile aqueous solutions, water-insoluble solutions, suspensions, emulsions, lyophilized agents, and suppositories, and may be in various oral or parenteral dosage forms. When compounding, it is prepared using commonly used fillers, bulking agents, binders, wetting agents, disintegrants, or diluents or excipients such as surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, or capsules, and these solid dosage forms are prepared by mixing one or more compounds with at least one or more excipients, such as starch, calcium carbonate, sucrose or lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, fragrances, and preservatives. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, or suppositories. Non-aqueous solvents and suspensions that can be used include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

[0042] In one aspect of the present disclosure, the pharmaceutical composition may be administered in a pharmaceutically effective amount. The “pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit-risk ratio applicable to medical treatment, and the effective dose level can be determined based on factors including the individual's species and severity, age, sex, type of disease, drug activity, sensitivity to the drug, administration time, route of administration and elimination rate, duration of treatment, concomitant medications, and other factors well known in the medical field. The compositions of the present disclosure may be administered as individual therapeutic agents, in combination with other therapeutic agents, or sequentially or concurrently with conventional therapeutic agents. They may also be administered as a single or multiple doses. It is important to administer an amount that takes all of the above factors into consideration and provides the greatest effect with the minimum amount without side effects, which is readily achievable by those skilled in the art. The preferred dosage of the composition disclosed herein varies depending on the patient's condition and weight, the severity of the disease, the form of the drug, the route of administration, and the duration of treatment. The appropriate total daily dose can be determined by the treating physician within the correct range of medical judgment, but generally, an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, may be administered once a day or in several divided doses. The target organism for administration of the composition is not particularly limited. For example, it is applicable to any organism, including non-human animals such as monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cattle, sheep, pigs, and goats, as well as humans. The method of administration is not limited to the usual methods in the industry. For example, transdermal administration methods such as topical application can be used, but are not limited to these.

[0043] In one aspect of the present disclosure, the cosmetic composition may include not only common auxiliaries, such as fatty substances, organic solvents, solvents, concentrates, gelling agents, softening agents, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestering agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic surfactants, or lipid vesicles, but also auxiliaries commonly used in the fields of cosmetics or dermatology.

[0044] In one aspect of this disclosure, the cosmetic composition may be a functional cosmetic. A functional cosmetic is a product that incorporates the specialized therapeutic functions of a pharmaceutical into a cosmetic and has specialized functionality that emphasizes physiologically active efficacy and effects, and includes products that help whiten the skin, products that help improve wrinkles, cosmetics that help tan the skin nicely, and cosmetics that help protect the skin from ultraviolet rays. A functional cosmetic can produce skin-improving effects through effects such as promoting the synthesis of functional substances such as collagen, elastin, laminin, or HAS2. The dosage form is not particularly limited, but can be manufactured in the form of solutions, emulsions, suspensions, pastes, creams, lotions, gels, powders, sprays, surfactant-containing cleansers, oils, soaps, liquid detergents, bath additives, foundations, makeup bases, essences, lotions, foams, packs, softening waters, sunscreen creams, or sun oils. Preferably, it can be manufactured in the form of ointments for external use, softening lotions, nourishing lotions, nourishing creams, massage creams, essences, packs, emulsions, or oil gels, in which case the carrier used can be selectively used depending on the dosage form of the cosmetic.

[0045] One aspect of this disclosure provides a method for improving skin condition, comprising the step of transdermally administering an effective amount of a composition containing a peptide or a derivative thereof containing the amino acid sequence of chemical formula I to a subject requiring improvement of skin condition. Preferably, the improvement of skin condition may be an improvement in skin wrinkles or an improvement in skin lipid secretion.

[0046] In one aspect of this disclosure, the method for improving skin condition may include the steps of: preparing a subject body that requires improvement of skin wrinkles or skin lipid secretion; administering the composition transdermally at a rate of 1 ml per day for 4 weeks; and improving the skin condition of the subject body. Preferably, the improvement in skin condition may be improvement of skin wrinkles or improvement of skin lipid secretion.

[0047] In one aspect of the present disclosure, the skin condition improving composition may contain a physiologically acceptable medium. Such a physiologically acceptable medium means, but is not limited to, aqueous or hydroalcoholic solutions, water-in-oil emulsions, oil-in-water emulsions, micro-emulsions, aqueous gels, anhydrous gels, serums, vesicle dispersants, or powders. "Physiologically acceptable" means that the composition is suitable for topical or transdermal use when in contact with the mucous membranes, appendages (nails, hair), scalp, and skin of mammals, particularly humans, and the composition may be ingestible without toxicity, incompatibility, instability, allergic reactions, and other hazards, and may be injectable into the skin. Such a "physiologically acceptable medium" may be a common excipient of the composition.

[0048] In one embodiment of the present disclosure, the peptide or its derivative can be dissolved in a lipophilic matrix or a hydrophilic matrix using a solubilizing agent, as may be used depending on the application. The peptides may be combined at effective concentrations with other active ingredients that can act synergistically or additionally to enhance and achieve the desired effects described herein, for example, formulations such as: anti-aging, anti-fine line and anti-wrinkle, whitening, pro-pigmenting, hydration, moisturizing, slimming, exfoliation, anti-acne, anti-redness, anti-inflammatory, antioxidant / radical scavenger, complexion brightener, anti-glycation, volume-enhancing, reconstructive, anti-carbonylation, skin soothing, anti-hair regrowth, acts on the stratum corneum, skin-epidermal junction, heat shock protein (HSP) production, firmness, elasticity and skin tone, hair growth (eyelashes and eyebrows), eye contour (dark circles and under-eye bags), improved blood circulation, other peptides, or vitamins. These active ingredients may be obtained from plant materials such as traditional plant extracts or products of plant cell culture or fermentation.

[0049] In one embodiment of the present disclosure, the composition may be provided in the form of a solution, dispersion, emulsion, paste, or powder, as any conventional form or carrier. The composition may also be applied in a vehicle or as a premixture in a vector such as macro-, micro-, or nano-capsules; macro-, micro-, or nano-spheres; liposomes, oleosomes, or chylomicrons; macro-, micro-, or nanoparticles; or macro-, micro-, or nano-sponges; or micro- or nano-emulsions; or absorbed onto organic polymer powders, talc, bentonite, spores, or outer membranes, and other inorganic or organic supports.

[0050] In one aspect of the present disclosure, the composition may be used for skin protection or makeup applications on the face, body, hair, and body hair. The peptide or its derivatives may be delivered locally via fabrics, natural or synthetic fibers, wool, clothing materials, handkerchiefs, etc., by contact between these fabrics and the skin.

[0051] In one aspect of the present disclosure, the composition may include additional active substances in addition to the peptide or its derivative. Such additional active substances may include a non-limited, broad range of cosmetic and pharmaceutical ingredients commonly used in the skincare industry, as listed in the CTFA (International Cosmetic Ingredient Dictionary & Handbook (15th edition, 2014), published by the Personal Care Products Council, ex-the Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, DC). The aforementioned additional active substances include betaine, glycerol, ActimoistBio2 (trademark) (active organics), AquaCacteen (trademark) (Mibelle AG Cosmetics), Aquaphyline (trademark) (Silab), AquaregulK (trademark) (Solabia), Carciline (trademark) (Greentech), Codiavelane (trademark) (Biotech Marine), Dermaflux (trademark) (Arch Chemicals, Inc.), Hydra'Flow (trademark) (Sochibo), and Hydromoist L (Hydromoist L) (Trademark) (Symrise), RenovHyal (Trademark) (Soliance), Seamoss (Trademark) (Biotech Marine), Argireline (Trademark) (Lipotec's acetyl hexapeptide-3 brand name), Spilanthol or Gatuline Expression (Trademark), which are extracts of Acmella oleracea, and Boswellin (Trademark), which are Boswellia serrata.Extracts of serrata, DeepalinePVB (trademark) (Seppic), Syn-AKE (trademark) (Pentapharm), Ameliox (trademark), Bioxilift (trademark) (Silab), PhytoCellTec (trademark), Argan (Mibelle), PapilactylD (trademark) (Silab), Preventhelia (trademark) (Lipotec), Subliskin (trademark) (Sederma), Venuceane (trademark) (Sederma), Moist 24 (trademark) (Sederma), Vegesome Moist 24 24) (Trademark) (Sederma), Essenskin (Trademark) (Sederma), Juvinity (Trademark) (Sederma), Revidrat (Trademark) (Sederma), Resistem (Trademark) (Sederma), Chronodyn (Trademark) (Sederma), Kombuchka (Trademark) (Sederma), Chromocare (Trademark) (Sederma), Calmosensine (Trademark) (Sederma), Glycokin factor S S) (trademark) (Sederma), Biobustyl (trademark) (Sederma), Idealift (trademark) (Sederma), Ceramide 2 (trademark), Ceramide A (trademark), Ceramide HO3 (trademark) (Sederma), Legance (trademark) (Sederma), Intenslim (trademark) (Sederma), Prodizia (trademark) (Sederma), Beautifeye (trademark) (Sederma), NG - Shea Butter UnsaponifiablesExamples include Beurre de Karite (natural grade) (Sederma), Zingerslim (trademark) (Sederma), Meiritage (trademark) (Sederma), Senestem (trademark) (Sederma), Sebuless (trademark) (Sederma), Majestem (trademark) (Sederma), Apiscalp (trademark) (Sederma), Rubistem (trademark) (Sederma), or mixtures thereof. In addition, the aforementioned additional active substances include ivy, especially English ivy (Hedera Helix), Bupleurum chinensis, Bupleurum falcatum, Arnica montana L, rosemary (Rosmarinus officinalis N), marigold (Calendula officinalis), sage (Salvia officinalis L), Korean ginseng (Panax ginseng), ginkgo biloba, St. John's wort (Hyperycum Perforatum), Butcher's broom (Ruscus aculeatus L), and European meadowsweet (Meadowsweet) Meadowsweet (Filipendula ulmaria L), Big-flowered Java tea (Orthosiphon stamineus benth), Algae (Fucus Vesiculosus), Betula alba, Green tea, Cola nuts (Cola nipida), Horse chestnut, Bamboo, Pegaga (Centella asiatica)asiatica), heather, fucus, willow, mouse-ear, escin, cangzhu, chrysanthellum indicum, plants of the genus Armeniacea, Atractylodis Platicodon, Sinnomenum, Pharbitidis, Flemingia, Coleus, where Coleus refers to, for example, C. forskohlii, C. blumei, C. eschillori (C. These include C. esquirolii, C. scutellaroides, C. xanthantu, and C. Barbatus, where the extract of C. Barbatus is, for example, the root extract of Coleus barbatus, Ballote, Guioa, Davallia, Terminalia, Barringtonia, Trema, antirobia, cecropia, argania, dioscoreae, where dioscoreae is, for example, an extract of Dioscorea opposita or Mexican, Ammi visnaga visnaga), Siegesbeckia, where Siegesbeckia is particularly an extract of Siegesbeckia orientalis, an extract of azalea (Ericaceae) vegetables, particularly an extract of bilberry (Vaccinium angustifollium) or bearberry (Arctostaphylos uva ursi), aloe vera, plant extracts containing sterols (e.g., phytosterol), Manjista (a plant of the genus Rubia, particularly Rubia cordifolia)Extracts from Cordifolia, Guggal (extracted from Commiphora, especially Commiphora Mukul), kola extract, chamomile, red clover, kava extract (Kava Kava (trademark), manufactured by Sederma), Bacopa monieri extract (Bacocalmine (trademark), Sederma), sea whip extract, Spanish licorice extract, mulberry extract, bottlebrush (melaleuca (tea tree)) extract, Larrea dibarricata Extracts of *Divaricata*, *Rabdosia rubescens*, *Euglena gracilis*, *Fibraurea recisa Hirudinea*, *Chaparral Sorghum*, sunflower extract, *Enantia chlorantha*, *Mitracarpe of Spermacocea genus*, *Buchu barosma*, *Lawsonia inermis L*, *Adiantium Capillus-Veneris L*, *Chelidonium majus*, *Luffa cylindrica*, *Japanese Mandarin* (Citrus reticulata Blanco var. unshiu), and *Camelia*. sinensis), Imperata cylindrica, Glaucium flavum, Cupressus sempervirens, Polygonatum multiflorum, Lovely HemsleyaHemsleya), European elder (Sambucus Nigra), green bean (Phaseolus lunatus), striped gentian (Centaurium), large duckweed (Macrocystis Pyrifera), Turnera Diffusa, flowering sedge (Anemarrhena asphodeloides), dwarf portulaca (Portulaca pilosa), hops (Humulus lupulus), Arabica coffee plant (Coffea Plant extracts such as Arabica, Yerba Mate (Ilex Paraguariensis), Globularia Cordifolia, Albizzia julibrissin, Oxydendron arboretum, Zingimber Zerumbet Smith, Astragalus membranaceus, Atractylodes macrocephalae, Plantago lanceolata, Leontopodium alpinum, Mirabilis jalapa, or celery (Apium graveolens) can be used.

[0052] In one aspect of this disclosure, the following components may be used as the additional active substance. - Vialox (trademark) (INCI name: Pentapeptide-3 (synthetic peptide containing alanine, arginine, isoleucine, glycine, and proline)), Syn-Aake (trademark) (β-Ala-Pro-Dab-NH-Bzl), or Syn-Coll (trademark) (Pal-Lys-Val-Lys-OH), sold by Pentapharm. - Products sold by Lipotec include Argireline (trademark) (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (INCI name: Acetyl Hexapeptide-3)), Leuphasyl (trademark) (Tyr-D-Ala-Gly-Phe-Leu), Aldenine (trademark) (Gly-His-Lys), and Trylagen (trademark) (INCI name: Pseudoalteromona Fermented extract, hydrolyzed wheat protein, hydrolyzed soy protein, tripeptide-10 citrulline (reaction product of citrulline and tripeptide-10 (a synthetic peptide consisting of aspartic acid, isoleucine, and lysine)), tripeptide-1), Eyeseryl (trademark) (Ac-β-Ala-His-Ser-His), Serilesine (trademark) (Ser-Ile-Lys-Val-Ala-Val) (SEQ ID NO23) or Decorinyl (trademark) (INCI name: tripeptide-10 citrulline = reaction product of citrulline and tripeptide-10 (a synthetic peptide consisting of aspartic acid, isoleucine, and lysine)); - Collaxyl (trademark) (Gly-Pro-Gln-Gly-Pro-Gln) or Quintescine (trademark) (Cys-Gly), sold by Vincience; - Cytokinol (trademark) LS (casein hydrolysate), sold by Les Laboratoires Serobiologiques / Cognis; - Kollaren (trademark) (Gly-His-Lys), IP2000 (trademark) (Pal-Val-Tyr-Val), or Meliprene (trademark) (INCI name: Monofluoroheptapeptide-1, reaction product of acetic acid, and synthetic peptide containing arginine, glycine, glutamic acid, histidine, norleucine, p-fluorophenylalanine, and tryptophan) sold by the European Institute of Cellular Biology (L'Institut Europeen de Biologie Cellulaire); -Neutrazen (trademark) (Pal-His-D-Phe-Arg-NH2); or sold by Introvations Inc. - BONT-L-Peptide (trademark) (INCI name: palmitoylhexapeptide-19, reaction product of palmitic acid and hexapeptide-19 (a synthetic peptide consisting of asparagine, aspartic acid, lysine, and methionine)), Timp-Peptide (trademark) (INCI name: acetylhexapeptide-20, reaction product obtained by acetylation of hexapeptide-20 (a synthetic peptide consisting of alanine, glycine, lysine, valine, and proline)), or ECM Moduline (trademark) (INCI name: palmitoyltripeptide-28, reaction product of palmitic acid and tripeptide-28 (a synthetic peptide consisting of arginine, lysine, and phenylalanine)), sold by Infinitec Activos.

[0053] In one aspect of the present disclosure, the composition may include, as an additional active substance, at least one of the following: a vitamin B3 compound, a compound such as niacinamide or tocopherol, a retinoid compound such as retinol, hexamidine, alpha-lipoic acid, resveratrol or DHEA, or a compound selected from hyaluronic acid.

[0054] This disclosure provides applications for peptides or derivatives thereof comprising the amino acid sequence of chemical formula I for the production of compositions for improving skin condition. The peptides or derivatives thereof can be used to improve the condition of the skin and its appendages by inducing the synthesis of at least one molecule in the skin matrix.

[0055] In one embodiment of this disclosure, improvement of skin condition comprehensively means the process or effect of reducing, mitigating, healing, or reducing skin damage caused by intrinsic or extrinsic factors of the skin. For example, improvement of skin condition may include improvement of skin wrinkles, skin hydration, skin whitening, maintenance or improvement of skin elasticity, wound healing, anti-aging, improvement of lipid secretion, or mitigation or improvement of dermatitis. Furthermore, improvement of skin condition may include overall anti-aging, anti-wrinkle and fine surface improvement (softening the skin, filling wrinkles), improvement of the mechanical properties of the skin such as hardness and elasticity, increase in skin density (skin reconstructive effect), increase in skin volume (plumping effect), improvement of stretch marks, anti-spot, improvement of skin uniformity, improvement of luster, or improvement of skin pigmentation. Preferably, the improvement of skin condition may refer to improvement of skin wrinkles or improvement of sebum secretion.

[0056] In one aspect of this disclosure, the composition may contain other peptides or peptide compounds other than peptides or derivatives thereof that contain the amino acid sequence of chemical formula I. The other peptides or peptide compounds may be present in amounts of 1 × 10⁻¹⁶ units relative to the total weight of the composition. -7 % by weight to 20% by weight, preferably 1 × 10 -6 Weight %~10% by weight, comfortably 1×10 5 It may be included in the composition in an amount of % to 5% by weight.

[0057] All ingredients described in this disclosure preferably do not exceed the maximum usage amounts stipulated in relevant laws and regulations in countries such as Korea, China, the United States, Europe, and Japan (e.g., regulations concerning cosmetic safety standards (Korea), cosmetic safety technical standards (China), food safety standards (Korea), food additive standards (Korea), and health functional food standards (Korea)). In other words, preferably, the cosmetic compositions, topical skin preparation compositions, or pharmaceutical compositions according to this disclosure contain the ingredients according to this disclosure in amounts permitted by the relevant laws and regulations of each country. [Effects of the Invention]

[0058] The peptides or derivatives thereof for improving skin condition exhibit remarkably excellent skin condition improving effects. These peptides or derivatives can be used as active ingredients in functional cosmetic compositions or topical skin preparation compositions for use on the skin. [Modes for carrying out the invention]

[0059] The present invention will be described in detail below with reference to examples to aid in understanding the present invention. However, the examples of the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following examples. The examples of the present invention are provided to give a more complete explanation of the present invention to a person of average skill in the art. The raw materials used in the present invention were purchased from companies that sell them for commercial purposes as usual. Synthesis example: Method for synthesizing the peptide of chemical formula I. The peptide of chemical formula I can be synthesized by the following synthetic method. Step 1: A hydrazine derivative protected with a "9-fluorenylmethoxycarbonyl" (hereinafter abbreviated as "Fmoc") group is bonded to a carbonyl compound, and a link amide resin is reacted thereto to activate the N-terminus and produce a semicarbazide-type resin; Step 2: The step of removing the protecting group, the Fmoc group attached to the nitrogen end of the Fmoc-azagly-link amide resin (azagly:azagly, -NH-NH-CO-) from Step 1, by a deprotection reaction in which the protecting group is treated with a reaction solvent such as 20% piperidine / DMF (dimethylformamide); Step 3: After Step 2, sequentially add and react the amino acid derivatives Fmoc-Lys, Fmoc-Gly, Fmoc-Arg, Fmoc-Ser, Fmoc-Ser, Fmoc-Cys, Fmoc-Phe, Fmoc-Val, Fmoc-Asp, and Fmoc-Cys, all of which have amine terminals and side chains protected by protecting groups; Step 4: The step of obtaining the Fmoc group of the peptide to obtain a peptide resin by removing the Fmoc group of the peptide in the deprotection reaction of Step 2; Step 5: After adding a weakly acidic cleavage solution such as 2% TFA (trifluoroacetic acid) / DCM (dichloromethane) to the peptide resin from Step 4 to separate the peptide from the resin, the resin is removed; Step 6: After adding hydrazine solution to the separated peptide, a catalytic hydrogen transfer reaction is carried out using reagents such as pd / c (palladium / catalyst) and cyclohexadiene to remove the benzyl group, nitro group (NO2), and Cbz (benzyloxycarbonyl) from the side chain protecting groups, followed by purification using the resulting reversed-phase column and ion exchange resin; By performing a process that includes the above steps, the peptide of chemical formula I of this disclosure can be produced.

[0060] Manufacturing Example 1: Cosmetic composition for improving skin condition (skin lotion) Skin lotion compositions were prepared by conventional methods according to the formulations listed in Table 1 below.

[0061] [Table 1]

[0062] Manufacturing Example 2: Cosmetic composition for improving skin condition (scalp lotion) A scalp lotion composition was manufactured by a standard method according to the formulations listed in Table 2 below.

[0063] [Table 2]

[0064] Experimental Example 1: Inhibition of collagenase activity by sequence mutation Collagenase derived from rat pancreas was used as the collagenase, and the synthetic substrate N-(3-[2-Furyl]acryloyl)-Leu-Gly-Pro-Ala was used as the collagenase substrate. The buffer solution used was a solution of 50 mM trichine, 10 mM CaCl2·H2O, and 400 mM NaCl (pH 7.5). The synthetic substrate was dissolved in buffer to a concentration of 10 mM, and then diluted to a final concentration of 75 μM. The collagenase was dissolved in cold tertiary distilled water at 4°C to a concentration of 1 unit / ml, and then diluted in buffer to a final concentration of 0.05 unit / ml. Collagenase inhibitor candidates were tested at final concentrations of 25 ppm and 50 ppm. As a positive control group, epigallocatechin gallate (EGCG), which is known to have a collagenase inhibitory effect, was set to a final concentration of 50 ppm. The reaction was carried out in a 96-well plate at room temperature for 10 minutes. The absorbance was measured at 345 nm at 1-minute intervals using a spectrophotometer, and the maximum gradient of absorbance over time was calculated to determine the enzyme activity inhibition rate (oxygen activity inhibition rate).

[0065] [Table 3]

[0066] Experimental Example 2: Inhibition of collagenase and elastase activity by sequence reordering. To confirm the efficacy of peptide sequence reordering, collagenase activity was examined after sequence mutation, similar to Experimental Example 1. Human leukocyte-derived elastase was used, and the synthetic substrate MeOSuc-Ala-Ala-Pro-Val-pNA was used as the elastase substrate. A 100 mM Tris (pH 7.5) solution was used as the buffer. A final concentration of 0.2 mU of elastase was used after buffering. The synthetic substrate for elastase was prepared as a 100 mM solution using DMSO, and then diluted with buffer to a final concentration of 0.5 mM. A positive control group was set with quercetin, a known elastase inhibitor, at a concentration of 10 ppm. Candidate elastase inhibitors were added to final concentrations of 10 and 20 ppm. The reaction was carried out in a 96-well plate at room temperature for 20 minutes. The absorbance was measured at 405 nm at 1-minute intervals using a spectrophotometer, and the enzyme activity was determined by calculating the absorbance gradient over time.

[0067] For the active ingredient, a peptide sequence consisting of one of sequence numbers 14-16 was treated at 100 μg / ml, and the peptide sequence RKSLFVD was used as the control peptide for the test. The collagenase activity inhibition rate (%) and elastase activity inhibition rate (%) were calculated as the relative ratio of enzyme activity to the control group, and the results are shown in Table 4 below.

[0068] [Table 4]

[0069] As shown in Table 4 above, the peptides of SEQ ID NOs. 1-3, and their reverse sequences, the peptides of SEQ ID NOs. 14-16, all inhibited the activity of collagenase and elastase. This confirmed that compositions containing these peptides can be used for improving skin wrinkles, enhancing elasticity, or moisturizing.

[0070] Experimental Example 3: Inhibition of collagenase and elastase activity by N-terminal or C-terminal mutations in the sequence. To confirm whether or not mutations in the N-terminal or C-terminal region of the peptide sequence have efficacy, collagenase and elastase activity were examined after the sequence mutation, in the same manner as in Experimental Example 1.

[0071] [Table 5]

[0072] As shown in Table 5 above, substitution of the N-terminus or C-terminus of the peptide sequence of Sequence ID No. 1 significantly suppressed collagenase and elastase activity.

[0073] Experiment Example 4: Effect on improving skin wrinkles The wrinkle-improving effect of the skin condition-improving composition disclosed herein was tested on a total of 25 men and women. The 25 men and women were divided into five groups of five, and the wrinkle-improving effect of the product on the area around the eyes and forehead was tested for a total of four weeks using Comparative Example 1 and Examples 1-4.

[0074] Efficacy measurements were conducted before use, one week after use, two weeks after use, and four weeks after use. Furthermore, during the human application trial period, the use of any cosmetics containing active ingredients that could potentially affect the test results (e.g., functional cosmetics for skin whitening, wrinkle improvement, etc.) was strictly prohibited. The trial was conducted based on using 1 ml twice a day, morning and night, for four weeks.

[0075] Wrinkle measurements around the eyes and on the forehead were performed using a 3D skin imaging device, Antera 3D CS (Miravex Ltd., Ireland), by photographing the same left forehead area of ​​the subject before and after application of the test product. The saved images were converted to Wrinkles Medium mode, and the analysis of wrinkles around the eyes was performed by specifying the analysis range including the area using a circle (Cricle) with a diameter of 10.7 mm. Furthermore, the analysis of wrinkles around the eyes was performed by analyzing the Indentation index value, which represents the average roughness (Ra) of the wrinkles within the range, in units of AU. The analysis of wrinkles on the forehead was performed by analyzing the Depth value, which represents the average depth of the wrinkles within the range. The reduction rate of wrinkles around the eyes and on the forehead was expressed as a percentage compared to the untreated state. The measurement results are shown in Table 6 below as the wrinkle density reduction rate.

[0076] [Table 6]

[0077] The results shown in Table 6 above confirm that Examples 1-4, which contain peptides of Sequence ID No. 1-3 or 14, exhibit remarkably superior wrinkle-inhibiting effects.

[0078] Experimental Example 5: Effect of improving skin lipid secretion The lipid secretion inhibitory effect of the skin condition improving composition disclosed herein was tested on a total of 50 males and females. The 50 males and females were divided into 5 groups of 10 each, and Comparative Example 1 and Examples 1, 3, 5, and 6 were used. Examples 5 and 6 were prepared based on Example 1 in Table 1, by changing only the type of peptide. After washing the face and allowing it to air dry for 15 minutes, 1 ml of Comparative Example 1 was applied to the left forehead and cheek area, and 1 ml of Examples 1, 3, 5, or 6 was applied to the right forehead and cheek area, and the amount of lipid production was measured after 1 hour. The amount of lipid production was measured using a Sebbumeter. Comparative Example was applied to one cheek and Example to the other cheek, and the measurement was performed as a relative value to the Comparative Example, and the results are shown in Table 7.

[0079] [Table 7]

[0080] As can be seen from the results above, a high lipid secretion inhibitory effect was observed in Examples 1, 3, 5, or 6, which contained the peptide sequence of SEQ ID NO: 1, 2, 5, or 6. This demonstrates that the skin condition improving compositions of this disclosure, which contain SEQ ID NO: 1, 2, 5, or 6, can be used very effectively to suppress lipid secretion.

[0081] The aforementioned examples of dosage forms, such as skin lotions, are merely illustrative examples of the compositions for improving skin condition of this disclosure, and it will be obvious to those skilled in the art that the scope of the compositions of this disclosure is not limited to these dosage forms.

[0082]

Claims

1. A cosmetic composition for improving skin condition, comprising a peptide represented by the amino acid sequence of the following chemical formula I, a derivative thereof, or an isomer thereof as an active ingredient, wherein the derivative is selected from the group consisting of palmitoyl derivatives, derivatives to which a dansyl group is attached, or derivatives to which an acetyl group is attached: <Chemical formula I> X1-X2-X3-(S-S-C-F)-Y1-Y2-Y3 The above X1 is K or not present, X2 is G or not present, X3 is R or not present, Y1 is V or not present, Y2 is D or not present, and Y3 is C or not present. composition.

2. The cosmetic composition according to claim 1, wherein the improvement of skin condition includes one or more selected from the group consisting of improvement of skin wrinkles, improvement of skin elasticity, improvement of skin moisture, suppression of skin aging, and improvement of skin lipid secretion.

3. A peptide represented by the amino acid sequence of the following chemical formula I, or a derivative thereof, wherein the derivative is selected from the group consisting of palmitoyl derivatives, derivatives to which a dansyl group is attached, or derivatives to which an acetyl group is attached. The amino acid sequence of the aforementioned chemical formula I is selected from the group consisting of the amino acid sequences of SEQ ID NOs: 1 to 13. <Chemical formula I> X1-X2-X3-(S-S-C-F)-Y1-Y2-Y3 The above X1 is K or not present, X2 is G or not present, X3 is R or not present, Y1 is V or not present, Y2 is D or not present, and Y3 is C or not present. Peptides, their derivatives, or their isomers.

4. A peptide, a derivative thereof, or an isomer thereof, represented by any one amino acid sequence selected from the group consisting of the amino acid sequences of Sequence ID No. 14 to 16, wherein the derivative is selected from the group consisting of palmitoyl derivatives, derivatives to which a dansyl group is attached, or derivatives to which an acetyl group is attached.

5. A cosmetic composition for improving skin condition, comprising the peptide described in claim 3 or 4, or a derivative thereof, or an isomer thereof, as an active ingredient.

6. The cosmetic composition according to claim 5, wherein the improvement of skin condition includes one or more selected from the group consisting of improvement of skin wrinkles, improvement of skin elasticity, improvement of skin moisture, suppression of skin aging, and improvement of skin lipid secretion.

7. A cosmetic composition for improving skin condition, comprising a peptide having 90% or more sequence identity with the amino acid sequence of the following chemical formula I: <Chemical formula I> X1-X2-X3-(S-S-C-F)-Y1-Y2-Y3 X1 is K or not present, X2 is G or not present, X3 is R or not present, Y1 is V or not present, Y2 is D or not present, and Y3 is C or not present, and there are no mutations in the amino acid sequence in (S-S-C-F) in the chemical formula I. composition.

Images